A one-page summary of TB treatment for pharmacy and medical students: regimens, weight-based doses, side effects and the new short regimens.
Tuberculosis (TB) Drugs Pocket Card 2026
Drug-susceptible & drug-resistant TB · WHO 2025 / ATS-CDC-ERS-IDSA 2025
H = isoniazid · R = rifampicin · Z = pyrazinamide · E = ethambutol · P = rifapentine · M = moxifloxacin · B = bedaquiline · Pa = pretomanid · L = linezolid
Drug-susceptible TB: adults
- Standard 6 months: 2HRZE / 4HR (all ages, all forms; first choice in Pakistan NTP)
- 4-month option (≥12 y): 2HPZM / 2HPM: rifapentine 1200 mg + moxifloxacin 400 mg daily, with H and Z; not in pregnancy, weight <40 kg, or most extrapulmonary TB
- TB meningitis: 2HRZE / 10HR (12 months) + dexamethasone; WHO also allows a 6-month intensive high-dose option
- Bone / spine TB: Often extended to 9–12 months
Drug-susceptible TB: children
- Non-severe TB (3 mo–16 y): 4 months: 2HRZ(E) / 2HR
- Severe TB: 6 months: 2HRZE / 4HR
- Paediatric FDC: Dispersible RHZ 75/50/150 mg tablets, dosed by weight band
Daily doses (mg/kg)
- Isoniazid: Adult 5 (max 300 mg) · Child 10 (7–15)
- Rifampicin: Adult 10 (max 600 mg) · Child 15 (10–20)
- Pyrazinamide: Adult 25 (20–30) · Child 35 (30–40)
- Ethambutol: Adult 15 (15–20) · Child 20 (15–25)
- Adult FDC (HRZE 75/150/400/275): 30–39 kg: 2 tab · 40–54 kg: 3 tab · 55–70 kg: 4 tab · >70 kg: 5 tab
- Pyridoxine: 10–25 mg daily with H (all adults in Pakistan practice, essential in pregnancy, HIV, diabetes, alcohol, malnutrition)
Key side effects & monitoring
- Isoniazid: Hepatitis, peripheral neuropathy
- Rifampicin: Orange urine/tears, hepatitis, many interactions (OCPs, warfarin, DOACs, ARVs, azoles)
- Pyrazinamide: Hepatitis, raised uric acid, joint pain
- Ethambutol: Optic neuritis: check vision and red-green colour at baseline; stop if vision changes
- LFTs: Baseline in all; repeat if symptoms, liver disease, alcohol, HIV, pregnancy
- Stop drugs if: ALT >3× ULN with symptoms, or >5× ULN without symptoms; reintroduce one by one
- Sputum: Smear/culture at end of month 2, 5 and 6
Drug-resistant TB (RR/MDR)
- BPaLM (6 months): Bedaquiline + pretomanid + linezolid + moxifloxacin, age ≥14 y; drop M if fluoroquinolone resistant (BPaL)
- BDLLfxC (6 months): Bedaquiline + delamanid + linezolid + levofloxacin + clofazimine; usable in children and pregnancy
- 9-month regimens: Modified all-oral options (WHO 2025) when 6-month regimens are not suitable
- Monitor: ECG for QTc (B, M, clofazimine, delamanid), CBC and neuropathy/vision for linezolid
- Diagnosis: GeneXpert MTB/RIF for all presumptive TB; rifampicin resistance → refer to PMDT site
Special situations
- Pregnancy: HRZE 6 months is safe; add pyridoxine; avoid 4-month HPZM regimen
- HIV: Start ART within 2 weeks of TB treatment (8 weeks in TB meningitis); rifampicin with dolutegravir needs DTG 50 mg twice daily
- Liver disease: Use fewer hepatotoxic drugs; specialist input
- Renal failure (CrCl <30): Z and E 3 times weekly after dialysis; H and R normal
- TB preventive therapy: 3HP (weekly H+P × 12 doses), 1HP, 3HR, or 6H for contacts and people with HIV
Red flags: refer
- Treatment failure: Positive smear at month 5 or later
- Hepatitis: Jaundice, vomiting, ALT >5× ULN
- Vision loss: Stop ethambutol immediately
- Resistance: Any rifampicin resistance on GeneXpert
Sources: WHO Consolidated Guidelines on TB, Module 4: Treatment and care (2025); ATS/CDC/ERS/IDSA Clinical Practice Guideline on drug-susceptible TB (2025); Pakistan National TB Control Programme. For learning only; follow your local programme and prescriber.
Practical points for students
Treatment in Pakistan is free through the National TB Control Programme (NTP) at government DOTS centres. Always give TB drugs as a fixed-dose combination when possible, every day, under supervision, and finish the full course even when the patient feels better. Missed doses are the main cause of drug resistance.
Important: this card is for education and revision. Treatment decisions must follow local guidelines and the treating doctor. More pocket cards: Clinical Pocket Cards | disease summaries: Disease Pocket Cards
No comments:
Post a Comment